Respiratory Medicine
Volume 103, Issue 11 , Pages 1755-1763 , November 2009

Budesonide/formoterol effects on metalloproteolytic balance in TGFβ-activated human lung fibroblasts

  • Lizbet Todorova

      Affiliations

    • Experimental Medical Science, Lund University, Lund, Sweden
    • ,
  • Eylem Gürcan

      Affiliations

    • AstraZeneca R&D Lund, 221 87 Lund, Sweden
    • ,
  • Gunilla Westergren-Thorsson

      Affiliations

    • Experimental Medical Science, Lund University, Lund, Sweden
    • Corresponding Author InformationCorresponding author. Tel.: +46 46 222 33 14; fax: +46 46 211 34 17.
    • ,
  • Anna Miller-Larsson

      Affiliations

    • AstraZeneca R&D Lund, 221 87 Lund, Sweden

Received 16 November 2008 ,Accepted 25 March 2009.

References 

  1. Tang ML, Wilson JW, Stewart AG, Royce SG. Airway remodelling in asthma: current understanding and implications for future therapies. Pharmacol Ther. 2006;112:474–488
  2. Howell JE, McAnulty RJ. TGF-beta: its role in asthma and therapeutic potential. Curr Drug Targets. 2006;7:547–565
  3. Ohbayashi H, Shimokata K. Matrix metalloproteinase-9 and airway remodeling in asthma. Curr Drug Targets Inflamm Allergy. 2005;4:177–181
  4. Mattos W, Lim S, Russell R, Jatakanon A, Chung KF, Barnes PJ. Matrix metalloproteinase-9 expression in asthma: effect of asthma severity, allergen challenge, and inhaled corticosteroids. Chest. 2002;122:1543–1552
  5. Cataldo D, Munaut C, Noel A, Frankenne F, Bartsch P, Foidart JM, et al. MMP-2- and MMP-9-linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol. 2000;123:259–267
  6. Suzuki R, Kato T, Miyazaki Y, Iwata M, Noda Y, Takagi K, et al. Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in sputum from patients with bronchial asthma. J Asthma. 2001;38:477–484
  7. Lemjabbar H, Gosset P, Lamblin C, Tillie I, Hartmann D, Wallaert B, et al. Contribution of 92kDa gelatinase/type IV collagenase in bronchial inflammation during status asthmaticus. Am J Respir Crit Care Med. 1999;159:1298–1307
  8. Mautino G, Henriquet C, Jaffuel D, Bousquet J, Capony F. Tissue inhibitor of metalloproteinase-1 levels in bronchoalveolar lavage fluid from asthmatic subjects. Am J Respir Crit Care Med. 1999;160:324–330
  9. Vignola AM, Riccobono L, Mirabella A, Profita M, Chanez P, Bellia V, et al. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med. 1998;158:1945–1950
  10. Matsumoto H, Niimi A, Takemura M, Ueda T, Minakuchi M, Tabuena R, et al. Relationship of airway wall thickening to an imbalance between matrix metalloproteinase-9 and its inhibitor in asthma. Thorax. 2005;60:277–281
  11. Vignola AM, Paganin F, Capieu L, Scichilone N, Bellia M, Maakel L, et al. Airway remodelling assessed by sputum and high-resolution computed tomography in asthma and COPD. Eur Respir J. 2004;24:910–917
  12. Kelly M, O'Connor T, Leigh R, Otis J, Gauvreau G, Gauldie J, et al. Inhaled budesonide/formoterol combination therapy significantly attenuates allergen-induced increases in airway myofibroblasts. Eur Respir J. 2007;30(Suppl. 51):137s;(P903)
  13. Capraz F, Kunter E, Cermik H, Ilvan A, Pocan S. The effect of inhaled budesonide and formoterol on bronchial remodeling and HRCT features in young asthmatics. Lung. 2007;185:89–96
  14. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med. 1993;4:197–250
  15. Roberts CR, Burke AK. Remodelling of the extracellular matrix in asthma: proteoglycan synthesis and degradation. Can Respir J. 1998;5:48–50
  16. Huang J, Olivenstein R, Taha R, Hamid Q, Ludwig M. Enhanced proteoglycan deposition in the airway wall of atopic asthmatics. Am J Respir Crit Care Med. 1999;160:725–729
  17. Westergren-Thorsson G, Chakir J, Lafreniere-Allard MJ, Boulet LP, Tremblay GM. Correlation between airway responsiveness and proteoglycan production by bronchial fibroblasts from normal and asthmatic subjects. Int J Biochem Cell Biol. 2002;34:1256–1267
  18. Todorova L, Gürcan E, Miller-Larsson A, Westergren-Thorsson G. Lung fibroblast proteoglycan production induced by serum is inhibited by budesonide and formoterol. Am J Respir Cell Mol Biol. 2006;34:92–100
  19. Westergren-Thorsson G, Önnervik PO, Fransson LÅ, Malmström A. Proliferation of cultured fibroblasts is inhibited by L-iduronate-containing glycosaminoglycans. J Cell Physiol. 1991;147:523–530
  20. Westergren-Thorsson G, Malmström J, Marko-Varga G. Proteomics – the protein expression technology to study connective tissue biology. J Pharm Biomed Anal. 2001;24:815–824
  21. Malmström J, Westergren-Thorsson G, Marko-Varga G. A proteomic approach to mimic fibrosis disease evolvement by an in vitro cell line. Electrophoresis. 2001;22:1776–1784
  22. Van den Bosch JM, Westermann CJ, Aumann J, Edsbäcker S, Tönnesson M, Selroos O. Relationship between lung tissue and blood plasma concentrations of inhaled budesonide. Biopharm Drug Dispos. 1993;14:455–459
  23. Iozzo R. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem. 1998;67:609–652
  24. Mautino G, Oliver N, Chanez P, Bousquet J, Capony F. Increased release of matrix metalloproteinase-9 in bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics. Am J Respir Cell Mol Biol. 1997;17:583–591
  25. Kelly EA, Busse WW, Jarjour NN. Increased matrix metalloproteinase-9 in the airway after allergen challenge. Am J Respir Crit Care Med. 2000;162:1157–1161
  26. Lee YC, Lee HB, Rhee YK, Song CH. The involvement of matrix metalloproteinase-9 in airway inflammation of patients with acute asthma. Clin Exp Allergy. 2001;31:1623–1630
  27. Wenzel SE, Balzar S, Cundall M, Chu HW. Subepithelial basement membrane immunoreactivity for matrix metalloproteinase 9: association with asthma severity, neutrophilic inflammation, and wound repair. J Allergy Clin Immunol. 2003;111:1345–1352
  28. Giembycz MA, Kaur M, Leigh R, Newton R. A Holy Grail of asthma management: toward understanding how long-acting β2-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br J Pharmacol. 2008;153:1094–1104
  29. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur Respir J. 2002;19:182–191
  30. Mak JC, Rousell J, Haddad EB, Barnes PJ. Transforming growth factor-beta1 inhibits beta2-adrenoceptor gene transcription. Naunyn Schmiedeberg's Arch Pharmacol. 2000;362:520–525

☆ This study was supported by the Medical Faculty of Lund University, the Swedish Medical Research Council (11550) and AstraZeneca.

PII: S0954-6111(09)00102-4

doi: 10.1016/j.rmed.2009.03.018

Respiratory Medicine
Volume 103, Issue 11 , Pages 1755-1763 , November 2009

Article Tools

* Image Usage & Resolution